Translate the text from Welsh to English.



 
Mae proses IPFR GIG Cymru yn cael ei defnyddio gan holl fyrddau iechyd y wlad wrth benderfynu p'un a ddylid cynnig triniaethau nad ydynt ar gael fel arfer i glaf unigol ai peidio.   
  
Sefydlwyd yr adolygiad ym mis Gorffennaf 2016 gan ganolbwyntio'n benodol ar ystyried y meini prawf sy'n cael eu defnyddio i bennu amgylchiadau clinigol eithriadol ar gyfer IPFR a'r cyfle i leihau nifer y paneli IPFR yng Nghymru. Roedd safbwynt y claf yn rhan amlwg o'r adolygiad.  
  
Cyhoeddwyd canfyddiadau cynhwysfawr yr adolygiad ym mis Ionawr, ac mae modd gweld yr adroddiad yma.  
  
Cyn ei Ddatganiad Llafar yn y Senedd y prynhawn yma, dywedodd Vaughan Gething:

 
> “Rydw i wedi trin yr adolygiad hwn o'r cychwyn mewn ffordd agored, gynhwysol a thryloyw, gan gynnwys yr holl bleidiau gwleidyddol, y cyhoedd a'r Gwasanaeth Iechyd Gwladol.    
>   
> "Rwy'n falch o weld consensws bod y darn hwn o waith yn un defnyddiol iawn, sy'n cynnig argymhellion ystyriol ac ymarferol i helpu byrddau iechyd i wneud penderfyniadau sy'n gallu bod yn rhai sensitif a chymhleth iawn.  Rwy'n arbennig o falch gweld llais y claf yn cael lle amlwg yn yr adroddiad.    
>   
> "Y newyddion da sy'n codi o'r adroddiad yw bod sawl agwedd o'r system yn gweithio'n dda, ac mae'r grŵp adolygu wedi gwneud argymhellion defnyddiol i gryfhau'r rheiny a gwella agweddau eraill o'r broses.  
>   
> "Daeth yr adolygiad i'r casgliad y dylai penderfyniadau ynghylch mynediad at driniaeth i gleifion unigol gael eu seilio ar lefel y manteision clinigol disgwyliedig ac a yw'r driniaeth yn cynnig gwerth rhesymol am arian.   
>   
> "O ran lleihau nifer y paneli IPFR, mae'r grŵp adolygu wedi argymell nad dyna'r ffordd orau ymlaen.    
>   
> "Mae'r adolygiad wedi awgrymu gwelliannau i'r broses yn gyffredinol i helpu'r byrddau iechyd i wneud y penderfyniadau cymhleth a sensitif iawn hyn.  Mae hyn yn cynnwys egluro pryd y mae'n briodol defnyddio'r broses IPFR, a chryfau sicrwydd ansawdd.  
>   
> “Hoffwn i ddiolch i'r grŵp adolygu, unwaith eto am eu gwaith caled a'u hymrwymiad i gwblhau'r darn cymhleth hwn o  waith. Hefyd hoffwn ddiolch i'r holl gleifion sydd wedi bod yn rhan o'r broses adolygu. Mae'r dystiolaeth a gafodd ei darparu yn y gweithdai a gynhaliwyd ar draws Cymru wedi bod yn werthfawr tu hwnt.  
>   
> “Rydw i wedi ysgrifennu at y byrddau iechyd i gyd i gadarnhau y bydd yr argymhellion yn cael eu rhoi ar waith erbyn mis Medi.  
>   
> "Rwy'n credu y bydd argymhellion yr adroddiad hwn, o'u rhoi ar waith, yn cael effaith gadarnhaol ar y broses IPFR. Bydd hyn yn golygu bod y system yn haws ei deall ac yn llai tebygol o gael ei cham\-ddefnyddio.  Rwy'n siŵr y bydd pobl Cymru'n croesawu hynny."







Translation:


 
The NHS Wales IPFR process is the mechanism used by all health boards in Wales to make decisions on access to treatments that are not routinely available for individual patients.  
  
The review was established in July 2016 with a particular focus on considering the “clinical exceptionality” decision making criteria for IPFR and the scope to reduce the number of IPFR panels in Wales. Central to the review was the patient perspective.  
  
The review’s comprehensive findings were published in January and are available here.  
  
Ahead of his Oral Statement in the Senedd this afternoon, Vaughan Gething said:

 
> “My approach to this review has been to be open, inclusive and transparent from the outset involving all political parties, the public and the NHS in Wales.    
>   
> “I’m pleased that the consensus is that this is a helpful piece of work that makes thoughtful and pragmatic recommendations that will help health boards deal with what are sensitive and very often complex decisions.  I am particularly pleased that the patient voice has centre stage in the report.    
>   
> “The good news from the report is that many aspects of the system are working well and the review group have made helpful recommendations to strengthen those and  improve upon other aspects of the process.  
>   
> “The review concluded that the principle for making decisions at an individual patient level about access to a treatment should be based upon the level of expected clinical benefit and whether the treatment offers reasonable value for money.   
>   
> “With regards to reducing the number of IPFR panels, the review group have recommended it would not be the best way forward.    
>   
> “The review has suggested improvements to the overall process to support health boards make these highly complex and sensitive decisions.  This includes clarifying when it is appropriate to use the IPFR process, and strengthening quality assurance.  
>   
> “I would like to thank the review group, once again, for their hard work and commitment in completing this complex piece of work. I would also like to express my gratitude to all of the patients who have been involved in the review process. The evidence they’ve provided in the workshops that have taken place across Wales has been invaluable.  
>   
> “I have written to all of the health boards to confirm the implementation of the recommendations by September.  
>   
> “I believe the recommendations in this report, when implemented, will have a positive impact on the IPFR process. It will make the system more easily understandable and less prone to being misused.  Something I’m sure the people of Wales will welcome.”